Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.440
+0.070 (5.11%)
Jan 22, 2026, 4:00 PM EST - Market closed
Akebia Therapeutics Revenue
Akebia Therapeutics had revenue of $58.77M in the quarter ending September 30, 2025, with 57.01% growth. This brings the company's revenue in the last twelve months to $225.07M, up 32.49% year-over-year. In the year 2024, Akebia Therapeutics had annual revenue of $160.18M, down -17.70%.
Revenue (ttm)
$225.07M
Revenue Growth
+32.49%
P/S Ratio
1.57
Revenue / Employee
$1,243,486
Employees
181
Market Cap
382.13M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 160.18M | -34.44M | -17.70% |
| Dec 31, 2023 | 194.62M | -97.86M | -33.46% |
| Dec 31, 2022 | 292.48M | 80.83M | 38.19% |
| Dec 31, 2021 | 211.65M | -82.99M | -28.17% |
| Dec 31, 2020 | 294.64M | -40.36M | -12.05% |
| Dec 31, 2019 | 335.00M | 127.26M | 61.26% |
| Dec 31, 2018 | 207.74M | 26.52M | 14.63% |
| Dec 31, 2017 | 181.23M | 179.69M | 11,706.32% |
| Dec 31, 2016 | 1.54M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Emergent BioSolutions | 788.90M |
| Organogenesis Holdings | 465.22M |
| Evolus | 285.82M |
| Aurora Cannabis | 263.57M |
| Canopy Growth | 200.02M |
| Kamada | 174.79M |
| SIGA Technologies | 172.25M |
| Lifecore Biomedical | 128.87M |
AKBA News
- 9 days ago - Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts - Seeking Alpha
- 10 days ago - Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook - GlobeNewsWire
- 16 days ago - Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS) - GlobeNewsWire
- 17 days ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Akebia Announces Establishment of Rare Kidney Disease Pipeline - GlobeNewsWire
- 7 weeks ago - Q32 Bio Sells Complement Inhibitor ADX-097 - PRNewsWire
- 2 months ago - Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 2 months ago - Akebia Therapeutics, Inc. (AKBA) Q3 2025 Earnings Call Transcript - Seeking Alpha